The PDUFA target action date is in the fourth quarter of 2026.
News|Articles|January 28, 2025
Key FDA decisions urologists can expect in the first half of 2025
Author(s)Hannah Clarke
Check out the key regulatory decisions set to happen early this year.
Advertisement
Advertisement
There are a number of pending FDA approvals that urologists should keep an eye on as we move through the first half of the year. These include new agents in prostate and bladder cancer, as well as a novel therapeutic for uncomplicated urinary tract infections (uUTIs).
Related to this article
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
A decision is expected by the fourth quarter of 2026.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Advertisement
Advertisement